Loading…
EVGN
Evogene Ltd.
NASDAQ· Healthcare· Biotechnology· CUSIP M4119S187
$0.55+2.16%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $8.68M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.75
- ROE
- -182.75%
- Profit margin
- 0.00%
- Revenue growth
- -60.70%
- Beta
- 0.68
- 52-week high
- $1.50
- 52-week low
- $0.37
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.4% over 5Y.
today you would have $15.75▼ -98.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.10 | $1.87 | $8.40 | $7.00 | |
| P/S | 8.4x | 2.5x | 2.2x | 14.2x | 17.2x |
| P/B | — | — | — | 3.5x | 1.0x |
| EPS | -$1.08 | -$2.89 | -$5.20 | -$6.50 | |
| Profit margin | -548.18% | -220.22% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XWELXWELL, Inc. | $1.01 | — | 20.6x | — | -361.36% | $8.68M |
| MGRXMangoceuticals Inc | $0.40 | — | 0.6x | — | -95.10% | $8.67M |
| NDRAENDRA Life Sciences Inc. | $5.80 | — | 1.4x | — | -152.04% | $8.7M |
| CODXCo-Diagnostics, Inc. | $1.21 |
About the company
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
- 38
- Rehovot, Israel
Company description provided by Yahoo Finance.